Artivion, Inc. (AORT) Stock Score, Valuation & Financial Research
Artivion, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for AORT
Artivion, Inc. currently has a Wall Street Score of 29/100. The stored market price is $24.65. Its financial score is 50/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Artivion, Inc. does
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aorti
AORT financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $24.65
- Market capitalization:
- $1.20B
- Revenue:
- $471.5M
- Net income:
- $-3.2M
- Free cash flow:
- $-911K
- Cash:
- $77.3M
- Total debt:
- $408.0M
- EPS:
- -0.06
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-911K, showing cash burn in the current stored period.
- The balance sheet shows $77.3M of cash versus $408.0M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: AORT increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AORT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.